Total mortality did not differ between cohorts however, there were significantly lower rates of both myocardial infarction (4% versus 12%, respectively HR, 0.22 P=0.006) and target vessel revascularization (6% versus 23%, respectively HR, 0.26 P=0.004) in the DES group. At a median follow-up of 503 days (range, 331 to 873 days), the cumulative incidence of major adverse cardiovascular events was lower in the DES cohort than in patients in the pre-DES group (24% versus 45%, respectively hazard ratio, 0.52 P=0.01). The 2 cohorts were well balanced for all baseline characteristics.

The first cohort consisted of 86 patients (19 protected LM) treated with bare metal stents (pre-DES group) the second cohort comprised 95 patients (15 protected LM) treated exclusively with DES. The impact of drug-eluting stent (DES) implantation on the incidence of major adverse cardiovascular events in patients undergoing percutaneous intervention for left main (LM) coronary disease is largely unknown.ДЇrom April 2001 to December 2003, 181 patients underwent percutaneous coronary intervention for LM stenosis at our institution.

Tsearch the m